Objective: The objective of this study was to systematically review and conduct a direct and network meta-analysis of randomized controlled trials that have examined the clinical safety and efficacy of using passive and active immunotherapies in Alzheimer's disease (AD).
antibody production and decrease inflammatory T cell activity in second-generation AD vaccine candidates [8, 9] .
The primary research question is "Is amyloid-based immunotherapy used in patients with the diagnosis of mildto-moderate AD (status according to the National Institute of Neurologic and Communicative Disorders and StrokeAlzheimer's Disease and Related Disorders Association criteria) associated with more benefits than harms compared to placebo?" The secondary research questions were "Which immunotherapy agent is associated with more comparative benefit (intra-class ranking in terms of clinical efficacy)?" and "Is passive, or active immunotherapy associated with more benefits?"
Methods

Systematic search of the literature
This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Review and MetaAnalysis (PRISMA) guidelines [10] . This report adheres to the recommendations of the PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions [11] .
The search strategy was performed by an information specialist (KC) in collaboration with the primary investigator (NF) in MEDLINE and EMBASE using the Ovid interface, and in the Cochrane Central Register of Controlled Trials (CENTRAL). Clinical trials were followed in clinicaltrials.gov database and the grey literature was searched for news or specific announcements about the medications under research and development. Search filters for the concepts of AD; immunotherapy and Aβ peptide were constructed using a combination of database MESH headings and text words. Database terms were adapted for each electronic database searched, no language restrictions were applied.
The research question and study eligibility criteria for this systematic review are based upon the following PICOS descriptions [12] : Population: All adults with clinical diagnosis of mild-tomoderate AD according to standardized diagnostic criteria (according to the National Institute of Neurologic and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association). Intervention: Any medicines used for active or passive immunotherapy (bapineuzumab, AAB-001, MABT5102A, ponezumab, PF-04360365, gantenerumab, RO4909832, solanezumab, LY2062430, BAN2401, GSK933776, AFFITOPE, AN1792, CAD106, semagacestat, LY450139, γ-secretase inhibitor, tramiprosate, 3APS, homotaurine, ALZHEMED, IVIG) Comparators: Immunotherapies-passive and active (interclass comparison; head-to-head studies) or placebo
Outcomes:
• Alzheimer's disease Assessment Scale-cognitive subscales (ADAS-cog) [ 
Study types:
Published or unpublished studies that were completed (with results) from phase 2 and phase 3 randomized controlled trials (RCTs) on humans, in any language. Studies were excluded if they were (1) post hoc analyses of previous RCTs, (2) non-RCTs, (3) studies with same population (duplication) and (4) trials that did not measure primary clinical outcomes or did not report required data. Study selection, data abstraction and quality assessment Two authors (NF and RH) independently selected studies for inclusion in this review. From the titles and abstracts of all studies identified by the electronic search, those that clearly did not satisfy inclusion criteria were excluded. Full texts were retrieved when either one or both of the reviewers decided to include it. Full copies of the studies considered eligible were then obtained and reviewed independently by the two reviewers to identify those suitable for inclusion in the analyses. Data extraction of included studies was also perfor med independently by the same reviewers. Disagreements or uncertainty were resolved by consensus.
The two review authors also independently assessed the risk of bias for included RCTs using the Cochrane Collaboration's Risk of Bias tool and abstracted data using a study-specific data extraction form. Again, disagreements were resolved by consensus.
Measures of treatment effect
The pairwise relative treatment effects of the competing interventions were estimated by calculating effect sizes as risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous outcome data (e.g., mortality), and by calculating mean differences with 95% CIs for continuous outcome data. For scales such as ADAS-cog, where a higher score indicates an increased disease severity, a negative mean difference vs placebo or other drugs is favorable and the drug will have a low rank.
Data synthesis, direct and network meta-analyses
A standard pairwise meta-analyses on the results was performed when data from included studies were available for any treatment comparison. A random-effects metaanalysis using an inverse variance weighting method was performed. Statistical heterogeneity was assessed by calculating separate heterogeneity variances for each pairwise comparison and by using Chi2 statistic and its P value, and the I2 statistic to quantify the percentage of variability that is due to true differences among studies rather than sampling error [14, 15] .
A random-effects network meta-analysis (NMA) was performed to obtain estimates for each comparison. In the absence of direct evidence for a given comparison, the indirect comparison provided the estimate. In the presence of direct evidence, the NMA is a combined estimate (i.e., direct and indirect evidence) [16] . In NMA, a common estimate was assumed for heterogeneity variance across different comparisons. We planned to combine direct and indirect estimates if the assumptions of between-study homogeneity, incoherence and transitivity across treatment comparisons were justifiable. Nonetheless, all the loops except one were open (all the interventions were only compared to placebo, none to each other), which meant that for most of the comparisons, there was no direct evidence. The only closed loop available was composed by three interventions that were only tested in a three-arms RCT [8] , and since loop incoherence cannot occur within a multi-arm trial [17] , we did not assess statistical incoherence.
A sensitivity analysis was performed to assess whether the findings of this review were robust to the decisions made in the process of obtaining them by conducting the following procedure: re-analysis excluding studies according to study quality issues, re-analysis including those with low or high risk of bias, re-analysis without imputing data for the missing participants and re-analysis using a random-effect model.
The ranking probabilities for each treatment were estimated. This is the probability that each treatment is the best, the second best, the third best, etc. in the network, based on the magnitude of the effects. Based on these probabilities we calculated the surface under the cumulative ranking curve (SUCRA), which is a summary of the rankings [18] . Surface under the cumulative ranking curve were expressed as a percentage and interpreted as the percentage of efficacy or safety of a treatment that would be ranked first without uncertainty. All the analyses were performed with STATA version 14 (StataCorp 2015).
Rating the confidence in estimates of the effect
We assessed the confidence in the estimates (also called quality of the evidence or certainty on the evidence) for ADAS-cog and mortality outcomes using the GRADE approach [19] . The confidence in the estimates was based on four levels: high, moderate; low; and very low. For the assessment of the confidence on the direct comparisons estimates, we rated both outcomes based on the traditional GRADE categories: risk of bias; imprecision; inconsistency; and publication bias [20] [21] [22] [23] [24] . Furthermore, following the GRADE guidance [25] , in a second step we removed the imprecision criterion to create direct GRADE quality assessments based only on four criteria (not rating down if imprecision was present, because this criterion was applied to the NMA estimate assessment, as is detailed below) to be used to inform the NMA estimates quality assessments.
We rated the confidence in the indirect comparisons focusing our assessments on loops connected to the interventions of interest through only one other intervention. A loop of evidence exists when two or more direct comparisons contribute to an indirect estimate [26] ; for example, when there are at least one study comparing intervention A vs intervention B, and at least one study comparing intervention A vs intervention C, the information from these two comparisons can be used to calculate an indirect estimate (indirect evidence) of a comparison B vs C. A loop is considered closed if direct evidence exists between B vs C (at least one study comparing B vs C) and will be considered an open loop when this direct evidence does not exist.
For the confidence assessment we followed the guidance provided by Puhan et al. [27] and Brignardello et al. [25] . In the previous example, we had evidence A vs B (AB) and A vs C (AC), and we indirectly estimated the effects of B vs C (BC). The indirect comparison confidence was the lowest of the confidence ratings we assigned to the two contributing direct comparisons [27] ; for instance, if AB had a confidence rated as moderate and BC had a confidence rated as high, the associated indirect comparison, AC, was judged as moderate confidence.
Furthermore, we had planned to rate down confidence in the indirect comparisons estimates further if we had a strong suspicion of intransitivity; however, transitivity was not suspected in any of the comparisons. Transitivity, also called similarity [28] , is the assumption that an indirect comparison is a valid method to compare two treatments because the studies are sufficiently similar in important clinical and methodological characteristics; in other words, that they are similar in their distributions of effect modifiers [29, 30] . For instance, following the scenario described above, in which we have evidence AB and BC but not AC, and the studies comparing AB are substantially different from studies comparing BC, in terms of characteristics of the population or the severity of the disease, we could define that there is intransitivity and, therefore, we would have reduced the confidence in the indirect estimate AC. As stated above, we did not identify intransitivity in any of the loops.
Lastly, we planned to rate the confidence in the NMA estimate for any pairwise comparison using the higher of the confidence rating amongst the contributing direct and indirect comparisons, and to rate down confidence in the network estimate when direct and indirect estimates have incoherence and/or imprecision [27] . Nevertheless, since there were no closed loops available, except one created by a three-arms trial, incoherence was not assessed in the comparisons and not considered in the closed loop.
Results
Search results and study selection
We retrieved references from Ovid MEDLINE (n= 509), Ovid EMBASE (n= 574), PubMed (n=31) and the CENTRAL (n=12) (Supplementary Material A). Moreover, six additional RCTs were identified from previous reviews reference list ( Figure 1 ). As shown in Figure 1 *High, high risk of bias; low, low risk of bias †All parties were blinded to treatment allocation except for the dispensing pharmacists, who were not involved in patient evaluation.
Study and patient characteristics
Methodological quality and risk of bias
As observed in Table 2 , the studies were found to be of "moderate" to "high risk of bias". Attrition bias (losses of follow-up) was >20% in two studies [32, 33] . Detection bias (blinding of assessors, which is important in the case of ADAS-cog, but not mortality) was also observed in most of the studies.
Efficacy assessment Alzheimer's disease Assessment Scale-cognitive subscales (ADAS-cog):
In terms of direct evidence, as per the efficacy primary ADAS-cog outcome, nine articles however, the ADAS-Cog is a detailed cognitive assessment for dementia for which a four-point difference between treatment groups is required to be considered a significant difference in the clinical practice setting which was not achieved in the present analysis ( Figure 2 ). Supplementary Material B) . Consequently, the results of "ranking probabilities for competing treatments" or SUCRA command, solanezumab 400 mg is reported as the best therapeutic choice having measured cognitive outcomes of patients with the ADAS-cog scale ( Figure B.2,  Supplementary Material B) . There was no change in ranking results of low attrition bias studies after the sensitivity analysis.
Clinical Dementia Rating-Sum of Boxes (CDR-SB):
The direct meta-analysis results showed a statistically but not clinically sign ifica n t differ en ce in favo r o f p la ceb o vs immunotherapies (mean difference=0.11, 95% CI 0.10, 0.12, P=0.001) from the six studies (eleven comparisons) evaluating efficacy of AN1792 (N= 44), bapineuzumab 0.5 mg/kg (N= 972), bapineuzumab 1 mg/kg (N= 307), solanezumab 400 mg (N= 1,027), semagacestat 140 mg (N= 494), IVIG 0.4 g/kg (N= 6), 3APS 150 mg (N= 233) and ACC-001 +/-QS-21 (N= 184) in patients with the CDR-SB scale. No change was observed in the results following a sensitivity analysis assessing studies with low vs high risk of bias. The results of "ranking probabilities for competing treatments" or SUCRA command, an active immunotherapy
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Randomization was stratified according to the use or nonuse of a cholinesterase inhibitor or memantine, baseline MMSE total score (16 to 21 vs 22 to 26), participation in a substudy, and, in the carrier study, APOE ε4 copy number (1 vs 2 Figure B.3, Supplementary Material B) . As with the ADAScog, the higher the score; the worst the cognitive condition. Supplementary Material B) , the direct metaanalysis results showed a statistically significant difference between drug therapies and placebo (MD=0.04, 95% CI 0.02, 0.05, P=0.00). According to the results for the SUCRA command, solanezumab 400 mg has been reported as the best therapeutic choice using the MMSE scale ( Figure B .4, Supplementary Material B). No change in ranking was observed in the therapeutic ranking results following a sensitivity analysis assessing studies with low vs high loss of follow-up [32, 33] .
Mini-Mental State examination (MMSE):
Safety assessment Amyloid related imaging abnormalities with edema (ARIA-E):
Three studies [5, 6] reported significantly higher rate of ARIA-E as RR= 9.3 (95% CI, 3.56, 24.35; P<.01), vs placebo in 4856 patients using monoclonal antibodies (bapineuzumab 0.5, N=995, 28%; bapineuzumab 1 mg/kg, N= 329, 13%; solanezumab 400 mg, N= 1,027, 1%) in mildto-moderate AD. Network comparison results (SUCRA)
showed that with respect to ARIA-E, solanezumab 400 mg is a safer alternative compare to bapineuzumab 0.5 and 1 mg/kg in mild-to-moderate AD patients.
Neoplasms-benign, malignant and unspecified:
The direct meta-analysis results showed a non-significant difference in rate of neoplasms between drug therapies and placebo (RR=1.14, 95% CI 0.53, 2.5, P=0.74) from four studies [5, 6, 33] repor ting rate of neoplasms in bapineuzumab 0.5 mg/kg (N= 785, 4.7%), 1 mg/kg (N= 329, 1.8%), solanezumab 400 mg (N= 1,027, 3.8%), semagacestat 140 mg (N= 527, 3%), vs placebo in 5,915 patients with mild-tomoderate AD. For neoplasms as a severe adverse event, the results for the S U C R A c o m m a n d r e p o r t e d bapineuzumab (0.5 and 1 mg/kg) as safer therapeutic alternatives compared w i t h s o l a n e z u m a b 4 0 0 m g a n d semagacestat 140 mg.
Mortality: Six articles [5] [6] [7] [8] 31, 33] reported death as a drug related severe adverse event: AN1792 225 mcg (N=300, 1.7%); bapineuzumab 0.5 mg/kg (N= 995, 3.5%); bapineuzumab 1 mg/kg (N= 329, 2%); solanezumab 400 mg (N= 1,027, 2.3%); semagacestat 140 mg (N= 527, 2.7%); IVIG 0.4 g/kg (N= 42, 0%); 3APS 150 mg (N= 347, 0.3%); and ACC-001 +/-QS-21 (N= 154, 1.3%). There was a non-significant difference between the rate of death in the immunotherapy group and the placebo (RR=1.40, 95% CI 0.96, 2.02, P=0.07) with the heterogeneity zero (I2=0.0%). The results of NMA and ranking probabilities of treatments, AN1792 225 mcg as an active immunotherapy resulted in the lowest rate of death and the second safer alternative as passive immunotherapy is solanezumab 400 mg ( Figure B .5, Supplementary Material B).
GRADE assessment
Overall the quality of the evidence was low to very low in most of comparisons for ADAS-cog changes and mortality. 
FIGURE 3. Network meta-analysis plot for the ADAS-cog scale
of the direct and NMA effect estimates and 95%CI for each comparison in terms of ADAS-cog mean difference, and the quality of the evidence assessment. Only the comparison IVIG 0.4 g vs placebo was rated as moderate quality, while semagacestat 140 mg vs placebo, ACC001+QS vs placebo, ACC001 vs placebo, and ACC001+QS vs ACC001 were rated as low quality and the rest of comparisons were rated as of very low quality. 
Discussion
To assess the potential benefits, safety and efficacy of immunotherapies reported in phase 2 and phase 3 clinical trials over last decade, a systematic review and network metaanalysis was performed to provide clinicians and researchers with best evidence and assist in determining future research and designing clinical trials. Although the network meta-analysis was not ideal given the lack of head-to-head studies among the interventions (i.e., only against placebo; a star-shaped network), except for one three-arm trial, interesting results were found. In efficacy assessment, the direct meta-analyses showed that immunotherapy vs placebo was statistically but not clinically significant in change from baseline in ADAS-cog and MMSE results [32, 33] . No clinical benefit in favor of immunotherapy was observed with the CDR-SB scale. The best alternative as a result of ranking probabilities was solanezumab 400 mg every four weeks (Q 4 W) for improving ADAS-cog, CDR-SB and MMSE scales. The use of AN1792 225 mcg as a vaccine, which is still under d e v e l o p m e n t d u e t o s e r i o u s a d v e r s e e v e n t s (meningoencephalitis), would be the second ranked active immunotherapy alternative for improving CDR-SB.
Three clinically-important serious adverse events were selected to be compared among immunotherapies and placebo (inter-and intra-group comparison). With respect to neoplasms and mortality, no significant differences were observed in direct comparisons vs placebo. Although the change in the rate of mortality outcome was not statistically significant, the study results showed a trend towards increasing mortality, and that significance might not achieved because of a low sample size. Perhaps further studies with more events, would have confirmed this trend. There was a significant higher rate of amyloid-related imaging abnor malities with edema (ARIA-E) obser ved in immunotherapy group vs placebo (RR= 9.3; 95%CI, 3.56, 24.35) .
According to the results of ranking probability matrix, the best alternatives were as follows: bapineuzumab 0.5 mg/ kg, bapineuzumab 1 mg/kg, solanezumab 400 mg and AN1792 225 mcg, which showed the lowest rates of neoplasms, ARIA-E and mortality. Considering that AN1792 225 mcg had a specific serious adverse event (meningoencephalitis), a safer alternative was solanezumab 400 mg, which showed the second lowest mortality.
Rankings and effect estimates should be analyzed together with the quality of the evidence. Several limitations in terms of risk of bias were found among most of the studies (lack of blinding of outcome assessors, significant losses of follow-up and allocation concealment flaws). This, along with additional limitations related to imprecision, meant that the quality of evidence for changes in ADAS-cog and the effect on mortality were judged to be very low for almost all the indirect comparisons obtained. For the direct comparisons of interventions vs placebo, only one comparison showed moderate quality in the ADAS-cog outcome, and four comparisons in the mortality outcome. Although the rankings provide us an idea of the effectiveness, the uncertainty around the estimates was quite high given the quality of the evidence.
The efficacy of IVIG 0.4 g/kg to reduce the ADAS-cog, was the only effect rated with moderate quality; therefore, the uncertainty around this was the lowest, but the results of this intervention was not different enough from the placebo to produce changes in the scores. Results with very low quality evidence were largely explained by the high risk of bias analyses.
The quality of evidence assessed by GRADE considered several criteria for the rating of evidence, and the presence of only indirect evidence (except for ACC001+QS vs ACC001) reduced the quality of evidence and resulted in the inability to calculate a NMA estimate. This was another reason for the final very low quality among almost all the indirect comparisons available.
The most important limitations observed in this review were 1) the absence of head-to-head trials, leading to mostly indirect estimates for all the comparisons among the interventions, 2) the short-term period of follow-up in the studies, 3) the losses of follow-up in some RCTs leading to a high risk of bias, 4) the absence of phase 3 clinical trials for some medications, 5) the termination of one RCT before completion due to severe adverse events, 6) the high rates of heterogeneity, mainly due to different follow-up periods and 7) the low number of included studies for each medication.
Summary
This analysis provides researchers with a clearer idea of the safety and efficacy of immunotherapies for AD that is based on best available evidence. Previously, there was no systematic review or meta-analysis making inter-and intragroup comparisons of safety and efficacy of amyloid-based immunotherapies in AD. We have systematically reviewed all the available published RCTs that examined the harm and benefit of using immunotherapy for AD. We summarized all the evidence and determined the comparative effectiveness of all the interventions. The present study is the first systematic review network meta-analysis of efficacy and safety of immunotherapies in the treatment of patients with mild-to-moderate AD. We limited the inclusion criteria to only published phase 2 and phase 3 RCTs to obtain the best evidence for addressing this important clinical issue in AD management.
Conclusions
This review results showed no clinically significant improvement in any AD-specific outcome measure scales (ADAS-cog, CDR-SB and MMSE) in favor of immunotherapies (passive and active) in mild-to-moderate AD. Solanezumab 400 mg was the drug of choice from both efficacy (ADAS-cog and MMSE) and safety (ARIA-E) perspectives and bapineuzumab 1 mg/kg showed the lowest risk of neoplasms compare with alternatives. Active immunotherapy (AN1792 225 mcg) showed better outcomes in both efficacy (CDR-SB) and mortality (vs passive immunotherapy) but had a potential specific serious adverse event (meningoencephalitis). To address this safety issue, vanutide cridificar (ACC-001) has been developed and has recently passed phase 2 clinical trials, showing an acceptable safety profile. Further high quality phase three RCTs, especially for vaccines and IVIG, are required to detect any meaningful differences in the cognitive endpoints using immunotherapies in mild-to-moderate AD.
